Nasus Pharma (NSRX) Stock Price Target 2026

The average analyst price target for Nasus Pharma is $16.50. Of 3 analysts, 3 rate it Buy. Targets range from $7 to $22. The latest change came on Oct 30, 2026, when Maxim Group initiated coverage of Nasus Pharma with a Buy rating and a $7 price target.

The Average Analyst Price Target for Nasus Pharma is $16.50.

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

1S.Buy

2Buy

Consensus RatingMarket Outperform# Analysts3Avg. Consensus PT$16.50

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Nasus Pharma Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Maxim Group	Naz Rahman	Initiate	Buy	$7
Mar 26, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$19→$18
Dec 18, 2025	Citizens	Jason Butler	Initiate	Market Outperform	$19
Sep 29, 2025	Laidlaw & Co.	Yale Jen	Initiate	Buy	$22

Analyst Ratings News

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).

Avi Kapoor

PRO
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7

Maxim Group analyst Naz Rahman initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.

Benzinga Newsdesk

PRO
Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19

Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outperform rating and announces Price Target of $19.

Benzinga Newsdesk

PRO
Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22

Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.

Benzinga Newsdesk

Nasus Pharma Ltd

Nasus Pharma (NSRX) Stock Price Target 2026

The Average Analyst Price Target for Nasus Pharma is $16.50.

Latest Upgrades and Downgrades for Nasus Pharma Stock

Analyst Ratings News

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

PRO
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7

PRO
Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

PRO
Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19

PRO
Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22

People Also Watch

People Also Watch

Nasus Pharma Ltd

Nasus Pharma (NSRX) Stock Price Target 2026

The Average Analyst Price Target for Nasus Pharma is $16.50.

Latest Upgrades and Downgrades for Nasus Pharma Stock

Analyst Ratings News

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

PROMaxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7

PROCitizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

PROCitizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19

PROLaidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22

People Also Watch

People Also Watch

PRO
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7

PRO
Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

PRO
Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19

PRO
Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22